FDA user fee reauthorization bill passes US House of Representatives

Home/Policies & Legislation | Posted 11/08/2017 post-comment0 Post your comment

The US House of Representatives passed a bill on 12 July 2017 reauthorizing the US Food and Drug Administration’s (FDA) prescription drug, generic drug, biosimilar and medical device user fee programmes.

User Fee V13H23

The user fee programmes are negotiated by FDA and pharma industry every five years and enable FDA to collect fees annually from drug and medical device makers. This funding is supplemental to what the US Congress appropriates to FDA each year and is intended to enable FDA to hire more staff, improve systems and establish a better managed review process to make therapies available to patients sooner without compromising review quality. The programmes have helped reduce backlogs at FDA, introduce innovative technologies and better engage patients. The current user fee programmes will expire on 30 September 2017 and the new versions will cover fiscal years 2018 to 2022.

Some amendments have been added since the last user fee authorization. Two amendments were added in the Senate hearing: Senator Hatch’s ‘expanded access amendment’ and Senators Collins and Franken’s ‘generic competition amendment’. The ‘generic competition amendment’, for example, allows for expedited review of priority generics [1].

With respect to biosimilars, FDA released a Biosimilar User Fee Act II (BsUFA II) performance goals letter, which outlined how the BsUFA II agreement would ‘help provide FDA with the resources needed to enhance the science-based review of new biosimilars, which will help increase competition in the marketplace to the benefit of patients’ [2].

The next step is for the Senate to pass the bill, however, despite the urgency, the Senate has not yet set forth its own timeline for voting on the bill.

Related article
FDA calls for comment on generics user fees guidelines

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA to speed up review of priority generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Aug 11]. Available from: www.gabionline.net/Guidelines/FDA-to-speed-up-review-of-priority-generics
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilar User Fee Act reauthorization [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Aug 11]. Available from: www.gabionline.net/Biosimilars/General/Biosimilar-User-Fee-Act-reauthorization

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

Source: Biocom,Whitehouse

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010